{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T03:33:40Z","timestamp":1794108820351,"version":"4.8.0"},"reference-count":32,"publisher":"American Association for Cancer Research (AACR)","issue":"4","funder":[{"DOI":"10.13039\/100000002","name":"HHS | National Institutes of Health (NIH)","doi-asserted-by":"publisher","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"HHS | National Institutes of Health (NIH)","doi-asserted-by":"publisher","award":["CA211615"],"award-info":[{"award-number":["CA211615"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"HHS | National Institutes of Health (NIH)","doi-asserted-by":"publisher","award":["CA201777"],"award-info":[{"award-number":["CA201777"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas (CPRIT)","doi-asserted-by":"publisher","award":["RP160710"],"award-info":[{"award-number":["RP160710"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,2,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>PARP1 inhibitors (PARPi) are currently used in the clinic for the treatment of ovarian and breast cancers, yet their therapeutic efficacy against hepatocellular carcinoma (HCC) has been disappointing. To ensure therapeutic efficacy of PARPi against HCC, a disease often diagnosed at intermediate to advanced stages with no effective treatment options, it is critical to identify not only biomarkers to predict PARPi resistance but also rational treatments to overcome this. Here, we report that a heterodimer of EGFR and MET interacts with and phosphorylates Y907 of PARP1 in the nucleus, which contributes to PARPi resistance. Inhibition of both EGFR and MET sensitized HCC cells to PARPi, and both EGFR and MET are known to be overexpressed in HCC. This report provides an explanation for the poor efficacy of PARPi against HCC and suggests combinatorial treatment consisting of EGFR, MET, and PARP inhibitors may be an effective therapeutic strategy in HCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Regulation of PARP by the c-MET and EGFR heterodimer suggests a potentially effective combination therapy to sensitize HCC to PARPi.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/0008-5472.can-18-1273","type":"journal-article","created":{"date-parts":[[2018,12,20]],"date-time":"2018-12-20T14:55:42Z","timestamp":1545317742000},"page":"819-829","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["EGFR and c-MET Cooperate to Enhance Resistance to PARP Inhibitors in Hepatocellular Carcinoma"],"prefix":"10.1158","volume":"79","author":[{"given":"Qiongzhu","family":"Dong","sequence":"first","affiliation":[{"name":"1Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."},{"name":"2Department of General Surgery, Huashan Hospital & Cancer Metastasis Institute & Institutes of Biomedical Sciences, Fudan University, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Du","sequence":"additional","affiliation":[{"name":"1Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[{"name":"1Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."},{"name":"3Liver Surgery Department, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunxiao","family":"Liu","sequence":"additional","affiliation":[{"name":"1Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongkun","family":"Wei","sequence":"additional","affiliation":[{"name":"1Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8027-8990","authenticated-orcid":false,"given":"Mei-Kuang","family":"Chen","sequence":"additional","affiliation":[{"name":"1Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."},{"name":"4Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xixi","family":"Zhao","sequence":"additional","affiliation":[{"name":"1Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Yi","family":"Chu","sequence":"additional","affiliation":[{"name":"1Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufan","family":"Qiu","sequence":"additional","affiliation":[{"name":"1Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lunxiu","family":"Qin","sequence":"additional","affiliation":[{"name":"2Department of General Surgery, Huashan Hospital & Cancer Metastasis Institute & Institutes of Biomedical Sciences, Fudan University, Shanghai, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohito","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"1Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mien-Chie","family":"Hung","sequence":"additional","affiliation":[{"name":"1Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."},{"name":"4Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston, Houston, Texas."},{"name":"5Graduate Institute of Biomedical Sciences and Center for Molecular Medicine, China Medical University, Taichung, Taiwan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2019,2,15]]},"reference":[{"key":"2022061706313479800_bib1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"2022061706313479800_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21332","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"2022061706313479800_bib3","doi-asserted-by":"crossref","first-page":"16018","DOI":"10.1038\/nrdp.2016.18","article-title":"Hepatocellular carcinoma","volume":"2","author":"Llovet","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"2022061706313479800_bib4","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"2022061706313479800_bib5","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"2022061706313479800_bib6","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/aps.2017.5","article-title":"New knowledge of the mechanisms of sorafenib resistance in liver cancer","volume":"38","author":"Zhu","year":"2017","journal-title":"Acta Pharmacol Sin"},{"key":"2022061706313479800_bib7","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrm1963","article-title":"Poly(ADP-ribose): novel functions for an old molecule","volume":"7","author":"Schreiber","year":"2006","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2022061706313479800_bib8","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/bjc.2011.382","article-title":"The role of PARP in DNA repair and its therapeutic exploitation","volume":"105","author":"Javle","year":"2011","journal-title":"Br J Cancer"},{"key":"2022061706313479800_bib9","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.molcel.2015.04.016","article-title":"Chromatin to clinic: the molecular rationale for PARP1 inhibitor function","volume":"58","author":"Feng","year":"2015","journal-title":"Mol Cell"},{"key":"2022061706313479800_bib10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nrclinonc.2014.163","article-title":"An update on PARP inhibitors\u2013moving to the adjuvant setting","volume":"12","author":"Sonnenblick","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"2022061706313479800_bib11","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/nm.4032","article-title":"Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors","volume":"22","author":"Du","year":"2016","journal-title":"Nat Med"},{"key":"2022061706313479800_bib12","doi-asserted-by":"crossref","first-page":"326","DOI":"10.2174\/1574887110666150729125809","article-title":"Clinical trials of poly(ADP-Ribose) polymerase inhibitors for cancer therapy: a review","volume":"10","author":"Buege","year":"2015","journal-title":"Rev Recent Clin Trials"},{"key":"2022061706313479800_bib13","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s00280-015-2852-2","article-title":"Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma","volume":"76","author":"Gabrielson","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"2022061706313479800_bib14","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jhep.2013.09.009","article-title":"Met as a therapeutic target in HCC: facts and hopes","volume":"60","author":"Giordano","year":"2014","journal-title":"J Hepatol"},{"key":"2022061706313479800_bib15","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/onc.2013.1","article-title":"Syntaxin 6-mediated Golgi translocation plays an important role in nuclear functions of EGFR through microtubule-dependent trafficking","volume":"33","author":"Du","year":"2014","journal-title":"Oncogene"},{"key":"2022061706313479800_bib16","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res"},{"key":"2022061706313479800_bib17","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1053\/jhep.2000.8525","article-title":"High-dose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential","volume":"32","author":"Wang","year":"2000","journal-title":"Hepatology"},{"key":"2022061706313479800_bib18","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0968-0004(03)00174-9","article-title":"Redox regulation of protein tyrosine phosphatases during receptor tyrosine kinase signal transduction","volume":"28","author":"Chiarugi","year":"2003","journal-title":"Trends Biochem Sci"},{"key":"2022061706313479800_bib19","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nrclinonc.2015.121","article-title":"Advances in targeted therapies for hepatocellular carcinoma in the genomic era","volume":"12","author":"Llovet","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"2022061706313479800_bib20","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2147\/JHC.S124366","article-title":"Optimal therapy for patients with hepatocellular carcinoma and resistance or intolerance to sorafenib: challenges and solutions","volume":"4","author":"Ray","year":"2017","journal-title":"J Hepatocell Carcinoma"},{"key":"2022061706313479800_bib21","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1158\/1078-0432.CCR-15-3069","article-title":"Randomized, placebo-controlled, phase ii study of veliparib in combination with carboplatin and paclitaxel for advanced\/metastatic non-small cell lung cancer","volume":"23","author":"Ramalingam","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2022061706313479800_bib22","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol"},{"key":"2022061706313479800_bib23","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","article-title":"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study","volume":"12","author":"Gelmon","year":"2011","journal-title":"Lancet Oncol"},{"key":"2022061706313479800_bib24","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med"},{"key":"2022061706313479800_bib25","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1158\/2159-8290.CD-12-0514","article-title":"Mechanisms of resistance to PARP inhibitors\u2013three and counting","volume":"3","author":"Fojo","year":"2013","journal-title":"Cancer Discov"},{"key":"2022061706313479800_bib26","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/nrc2812","article-title":"PARP inhibition: PARP1 and beyond","volume":"10","author":"Rouleau","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"2022061706313479800_bib27","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.cell.2010.03.012","article-title":"53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks","volume":"141","author":"Bunting","year":"2010","journal-title":"Cell"},{"key":"2022061706313479800_bib28","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1073\/pnas.1013715108","article-title":"Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells","volume":"108","author":"Patel","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061706313479800_bib29","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/nm.3993","article-title":"Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors","volume":"21","author":"Esposito","year":"2015","journal-title":"Nat Med"},{"key":"2022061706313479800_bib30","doi-asserted-by":"crossref","first-page":"e5933","DOI":"10.1371\/journal.pone.0005933","article-title":"Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2","volume":"4","author":"Kim","year":"2009","journal-title":"PLoS One"},{"key":"2022061706313479800_bib31","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1054\/bjoc.2000.1580","article-title":"Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma","volume":"84","author":"Ito","year":"2001","journal-title":"Br J Cancer"},{"key":"2022061706313479800_bib32","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1309\/WF10QAAED3PP93BH","article-title":"Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma","volume":"129","author":"Buckley","year":"2008","journal-title":"Am J Clin Pathol"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/79\/4\/819\/2786842\/819.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/79\/4\/819\/2786842\/819.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T15:17:51Z","timestamp":1655479071000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/79\/4\/819\/638957\/EGFR-and-c-MET-Cooperate-to-Enhance-Resistance-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,15]]},"references-count":32,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,2,15]]},"published-print":{"date-parts":[[2019,2,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-18-1273","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22421897","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22421897.v1","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6511067.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6511067","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,15]]}}}